What were the results of the CHANCE Trial regarding the efficacy of clopidogrel with aspirin in minor stroke or transient ischemic attack?
The CHANCE trial was a randomized clinical trial involving 20,000 participants that investigated the efficacy of clopidogrel with aspirin in minor stroke or transient ischemic attack. The results of the trial showed that clopidogrel with aspirin was associated with a statistically significant reduction in the risk of death, stroke or non-fatal myocardial infarction at the one-year follow-up compared to aspirin alone. Additionally, the trial also found that CYP2C19 loss-of-function allele status had a significant impact on the efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. Furthermore, the CHANCE trial also found that dual antiplatelet therapy was associated with a reduced risk of recurrent stroke in patients with different infarction patterns. Overall, the results of the CHANCE trial suggest that clopidogrel with aspirin is an effective treatment option for minor stroke or transient ischemic attack. 